medigraphic.com
ISSN 0210-5187 (Electronic)

2011, Number 1

<< Back Next >>

Med Cutan Iber Lat Am 2011; 39 (1)

Leishmaniasis, an emergent disease. Five clinical cases presentation

López-Giménez MT, Sánchez SP, Lahuerta AA, López-Borrachina R, Oncins TR, Griabal GM

Language: Spanish
References: 27
Page: 13-18
PDF size: 1563.73 Kb.


ABSTRACT

Infection whith protozoan parasites of the genus Leishmania causes a variety of clinical diseases called leishmaniases, which is transmited to human host by the bite of a sandfly. The clinical manifestation depends on the interaction among series of parasite and host inmunity: cutaneous, mucocutaneous or visceral. Worldwide, an estimated 12 million people are infected with leishmaniases. The number of cases of leishmaniases is increasing, globally at an alarming rate, and the leishmaniases are among in the top the emergent diseases. The ecological chaos, differents phenomena such as migration, immunosupression caused by drughs and viral infections, globalization of work and leisure contribute to the spread and increase of the disease. We report five cases with leishmaniasis who had been atended in 2007 at our hospital in Huesca (Spain), reflecting its clinical diversity..


REFERENCES

  1. García Almagro D. Leishmaniasis cutánea. Actas Dermosifilogr 2005; 96: 1-24.

  2. Quesada Cortés A, Campos Muñoz L, Rubio Flores C, Martín Diaz MA, Navarro Sánchez M, Regojo Zapata RM, Lucas de Laguna R, Herranz PintoP. Leishmaniasis cutánea: revisión y avances terapéuticos. Dermatol Practica 2005; 13: 11-22.

  3. Sánchez-Saldaña L, Saenz-Anduaga E, Pancorbo- Mendoza J, Zegarra-Del-Carpio R, Garcés-Velasco N, Regis-Roggero A. Leishmaniasis. Dermatol Per 2004; 14: 82-98.

  4. Shaw J. The Leishmaniasis-survival and expansion in a changing world. A mini-review. Mem Inst Oswaldo Cruz 2007; 102: 504-7.

  5. Mansueto P, Vitale G, Di Lorenzo G, Rini GB, MansuetoCillari E. Immunopathology of leishmaniasis: an update. Int J Immunopathol Pharmacol 2007; 20: 435-45.

  6. Valesky EM, Thaçi D, Meissner M, Beier C, Wolter M, Schöfer H, Kaufmann R. Cutaneous leishmaniasis: clinical report of two cases and review of the recent literature. J Dtsch Dermatol Ges 2007; 5: 770-2.

  7. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7: 581-96.

  8. Schwart E, Hatz C, Bllum J. New World Cutaneous leishmaniasis in travellers. Lancet Infect Dis 2007; 7: 581-96.

  9. Benvenuti F, Ribera-Pivernat M, Boada Garcia A, Ferrándiz C. Leishmaniasis cutánea múltiple: presentación de tres casos. Piel 2008; 23: 162-5.

  10. Hernández C, Cetner AS, Jordan E, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008; 59: 363-80.

  11. Orenstein R. and Matterson E. TNF inhibitors and infections. Infect Med 2006; 23: 99-114.

  12. Pizzorni C, Secchi ME, Cutolo M. Leishmaniasis in rheumatoid arthritis. Reumatismo 2007; 59: 235-9.

  13. Ritter U, Lechner A, Scharl K, Kiafard Z, Zwirner J, Körner H. TNF controls the infiltration of dendritic cells into the site of leishmania major infection. Med Microbiol immunol 2008; 1: 29-37.

  14. Von Stebut E. Immunopathology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritics cells for protective immunity. Eur J Dermatol 2007; 17: 115-22.

  15. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ trasplant recipients. Lancet Infect Dis 2008; 8: 191-9.

  16. Tuon FF, Amato VS, Floeter-Winter LM, Andrade Zampierini R, Amato Neto V, Siqueira França FS, Shikanai-Yasuda MA. Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids-first report. Int J Dermatol 2007; 46: 628-30.

  17. Marovich MA, Lira R. Shepard M. Leishmaniasis recurrence after 43 years:a clinical and immunologic reportafter succesful treatment. Clin Infect Dis 200; 33: 1976-9.

  18. Grande Tejada AM, Cardesa García JJ, Vagace Valero JM, García Domínguez M, Bejarano Ramírez N. Leishmaniasis visceral, a propósito de tres casos. Vox paedriatrica 2004; 12: 34-8.

  19. Bailey MS, Lockwood DN. Cutaneous Leishmaniasis. Clin Dermatol 2007; 25 (2): 203-11.

  20. Bari AU, Rahmans S. Many faces of cutaneous leishmaniasis. Indian J Dermatol, Venereol Leprol 2008; 74: 23-7.

  21. Zegarra-del-Carpio R, Sánchez-Saldaña L. Leishmaniasis cutánea: presentación en placa verrugosa. Dermatol Per 2005; 15: 62-5.

  22. Spanakos G, Piperaki E-T, Menaunos PG, Tegos N, Flemetakis A, Vakalis C. Detection and species identification of Old World Leishmania in clinical samples using a PCRbased method.Trans. R Soc Trop Med Hyg 2008; 102: 46-53.

  23. Schonian G, Mauricio I, Gramiccia C, Boelaert M, Dujardin JC. Leishmaniasis in the Mediterranean in the era of molecular epidemiology. Trends Parasitol 2008; 24: 135-42.

  24. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old Wordl cutaneous leishmaniasis: A systemic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57: 335-46.

  25. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006; 61: 223-74.

  26. Tuon FF, Amato VS, Siqueira AM, Nicodemo AC, Amato Neto V. Treatment of new world cutaneous leishmaniasis a systematic review with a meta-analysis. Int J dermatol 2008; 4: 109-24.

  27. Palatnik de Sousa C. Vaccinas for leishmaniasisin the fore coming 25 years. Vaccine 2008; 26: 1709-24.




2020     |     www.medigraphic.com